De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases

Authors:
  • JRJai Radhakrishnan
    Jai Radhakrishnan
  • DCDavid J. Cohen
    David J. Cohen
  • LSLeonard Stern
    Leonard Stern
  • MGMichael Goldstein
    Michael Goldstein
  • MHMark Hardy
    Mark Hardy
  • VDVivette D. D'Agati
    Vivette D. D'Agati

Abstract
The term thrombotic microangiopathy (TMA) has been applied to a diverse group of conditions that share the common pathomechanism of endothelial damage. TMA is a recognized complication of solid organ transplantation. The majority of cases represent de novo TMA, which occurs in ∼2.8–3.5% of renal transplant recipients and is associated with a 22% rate of graft loss [1]. The rate of graft loss is strongly influenced by whether the TMA is systemic or renal limited (38 vs 0% graft loss, respectively) [1].

This publication has 25 references indexed in Scilit: